The goal of this clinical trial is to determine whether hand and foot exercises can reduce the severity of Taxane-based chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients aged 20-60 years who have Grade 1I neuropathy as defined by the NCI-CTCAE criteria.
The main questions it aims to answer are:
* Do hand and foot exercises reduce the severity of sensory and motor neuropathic symptoms in patients receiving Taxane based chemotherapy? * Is the severity of peripheral neuropathy lower in the exercise group compared to patients receiving standard care alone? Researchers will compare patients receiving standard care (control group) with those receiving standard care plus a structured hand and foot exercise program (experimental group) to see if the exercises lead to greater improvement in neuropathy severity scores.
Participants will:
* Receive baseline assessment using the EORTC QLQ-CIPN20 questionnaire. * In the experimental group, learn and perform a 15-minute hand and foot exercise routine on chemotherapy day and continue it at home using a provided brochure. * Participate in telephonic follow-ups to support compliance and monitor symptoms. * Undergo a follow-up assessment at alternate week to measure changes in neuropathy severity.
Cancer patients receiving taxane-based chemotherapy on alternate week.
Age 20-60 years, both male and female.
Patients having Grade I neuropathy by NCI-CTCEA criteria.
Patients with peripheral neuropathy not caused by chemotherapy.
Patient with type-1 and type- 2 diabetes.
Patients with neuropsychiatric disorders.
Patients having any skin ulcer.
Parallel
Structured Hand and Foot Exercises
Other interventionThe intervention consists of a structured hand and foot exercise program specifically designed for patients experiencing chemotherapy-induced peripheral neuropathy during Taxane-based treatment. It is distinct from general physiotherapy or mobility exercises because it targets peripheral nerve function, joint mobility, and circulation in the hands and feet, aiming to reduce the severity of neuropathic symptoms.
Severity of peripheral neuropathy
The primary outcome of this study is the severity of chemotherapy-induced peripheral neuropathy in cancer patients receiving Taxane-based chemotherapy. Severity will be measured using the EORTC QLQ-CIPN20 questionnaire, which assesses sensory symptoms (tingling, numbness, burning), motor symptoms (difficulty gripping or walking), and autonomic symptoms (such as dizziness). Each item is scored from 1 (not at all) to 4 (very much), with higher scores indicating more severe neuropathy. Assessments will be conducted at baseline (week 1) and week 8 to determine whether the hand and foot exercise program reduces symptom severity compared to standard care alone.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
